Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Evaluation of Lipoic Acid as a Treatment for Geographic Atrophy Secondary to Age-Related Macular Degeneration (AMD): Phase I- Tolerability Study and Phase II Pilot- Determine the Effects of ALA on the Progression of Geographic Atrophy (GA) in Patients With Age-related Macular Degeneration (AMD).

NCT02613572 is registered in ClinicalTrials.gov with University of Pennsylvania as lead sponsor.

NCT NCT02613572
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02613572 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Evaluation of Lipoic Acid as a Treatment for Geographic Atrophy Secondary to Age-Related Macular Degeneration (AMD): Phase I- Tolerability Study and Phase II Pilot- Determine the Effects of ALA on the Progression of Geographic Atrophy (GA) in Patients With Age-related Macular Degeneration (AMD).
Lead sponsor
University of Pennsylvania
Phase
Phase 1/2
Overall status
Completed
Start date
November 30, 2015
Completion date
March 1, 2019
Enrollment
68 (actual)
Sites
5

Conditions

As the registry lists them; a condition with its own page is linked.

age-related macular degeneration